@poltreg.tech
Poltreg was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize the patented TREG method.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
About
Description
PolTREG | Gdansk is a leading biotechnology company founded in 2015 with headquarters and state-of-the-art laboratories located in Gdańsk. Our mission is to develop effective T-regulatory cell (TREG) based therapies for autoimmune diseases, aiming to improve the quality of life for patients and their families. We have already advanced four projects into the clinical stage of development, specifically targeting type 1 diabetes and multiple sclerosis.
Our portfolio also includes projects based on the next generation of genetically modified T-regulatory lymphocytes. Our team consists of experienced managers, biotechnology specialists, and scientists who have accumulated over 17 years of experience in using T-regulatory cells for autoimmune disease treatment. We are proud to have a Scientific Advisory Board comprising world-class opinion leaders.
Our strategy revolves around developing innovative therapies for autoimmune diseases using regulatory T lymphocytes (TREGs). We believe these cells play a crucial role in the immune system and hold significant potential for treating these diseases. Our long-term objective is to leverage the therapy platform we have created to develop additional therapies for conditions like amyotrophic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and other autoimmune diseases.
We are also working on developing new generation products such as CAR-TREGs and tissue-specific TREGs. In parallel, we are constructing a modern manufacturing facility that will be one of the most advanced in Europe for cell and gene therapy manufacturing. The facility will enable us to manufacture our own products at scale and provide contract development and manufacturing operation (CDMO) services to third parties.
This proximity to treatment is important for TREG-based therapies and associated technology, making our facility a valuable resource for future partners targeting the European market. With our focus on research, development, and innovation, PolTREG | Gdansk aims to become a global leader in the field of autoimmune disease therapy. Reach out to us to learn more about our pioneering work and how we are revolutionizing the future of medicine
Company Type
Privately Held
Company Size
2-10
Year Founded
2015
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online